Navigation Links
Researchers decipher manic gene
Date:8/31/2012

Flying high, or down in the dumps - individuals suffering from bipolar disorder alternate between depressive and manic episodes. Researchers from the University of Bonn and the Central Institute of Mental Health in Mannheim have now discovered, based on patient data and animal models, how the NCAN gene results in the manic symptoms of bipolar disorder. The results have been published in the current issue of "The American Journal of Psychiatry."

Individuals with bipolar disorder are on an emotional rollercoaster. During depressive phases, they suffer from depression, diminished drive and often, also from suicidal thoughts. The manic episodes, however, are characterized by restlessness, euphoria, and delusions of grandeur. The genesis of this disease probably has both hereditary components as well as psychosocial environmental factors.

The NCAN gene plays a major part in how manias manifest

"It has been known that the NCAN gene plays an essential part in bipolar disorder," reports Prof. Dr. Markus M. Nthen, Director of the Institute of Human Genetics at the University of Bonn. "But until now, the functional connection has not been clear." In a large-scale study, researchers led by the University of Bonn and the Central Institute of Mental Health in Mannheim have now shown how the NCAN gene contributes to the genesis of mania. To do so, they evaluated the genetic data and the related descriptions of symptoms from 1218 patients with differing ratios between the manic and depressive components of bipolar disorder.

Comprehensive data from patients and animal models

Using the patients' detailed clinical data, the researchers tested statistically which of the symptoms are especially closely related to the NCAN gene. "Here it became obvious that the NCAN gene is very closely and quite specifically correlated with the manic symptoms," says Prof. Dr. Marcella Rietschel from the Central Institute of Mental Health in Mannheim. According to the data the gene is, however, not responsible for the depressive episodes in bipolar disorder.

Manic mice drank from sugar solution with abandon

A team working with Prof. Dr. Andreas Zimmer, Director of the Institute of Molecular Psychiatry at the University of Bonn, examined the molecular causes effected by the NCAN gene. The researchers studied mice in which the gene had been "knocked out." "It was shown that these animals had no depressive component in their behaviors, only manic ones," says Prof. Zimmer. These knockout mice were, e.g., considerably more active than the control group and showed a higher level of risk-taking behavior. In addition, they tended to exhibit increased reward-seeking behavior, which manifested itself by their unrestrained drinking from a sugar solution offered by the researchers.

Lithium therapy also effective against hyperactivity in mice

Finally, the researchers gave the manic knockout mice lithium a standard therapy for humans. "The lithium dosage completely stopped the animals' hyperactive behavior," reports Prof. Zimmer. So the results also matched for lithium; the responses of humans and mice regarding the NCAN gene were practically identical. It has been known from prior studies that knocking out the NCAN gene results in a developmental disorder in the brain due to the fact that the production of the neurocan protein is stopped. "As a consequence of this molecular defect, the individuals affected apparently develop manic symptoms later," says Prof. Zimmer.

Opportunity for new therapies

Now the scientists want to perform further studies of the molecular connections of this disorder - also with a view towards new therapies. "We were quite surprised to see how closely the findings for mice and the patients correlated," says Prof. Nthen. "This level of significance is very rare." With a view towards mania, the agreement between the findings opens up the opportunity to do further molecular studies on the mouse model, whose results will very likely also be applicable to humans. "This is a great prerequisite for advancing the development of new drugs for mania therapy," believes Prof. Rietschel.


'/>"/>

Contact: Dr. Markus M. Nthen
markus.noethen@uni-bonn.de
0049-228-287-22347
University of Bonn
Source:Eurekalert

Related medicine news :

1. Cleveland Clinic researchers investigating potential drug for treatment of Alzheimers disease
2. BUSM researchers study use of MRI in osteoarthritis
3. Wayne State researchers say adolescent smoking prevention programs still critical
4. WSU researchers discover mechanism leading from trichomoniasis to prostate cancer
5. URMC researchers connect new genetic signature to leukemia
6. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
7. In war with superbugs, Cedars-Sinai researchers see new weapon: Immune-boosting vitamin
8. Midlife fitness staves off chronic disease at end of life, UT Southwestern researchers report
9. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
10. Cramming for a test? Dont do it, say UCLA researchers
11. Brigham and Womens Hospital researchers initiate major cardiovascular inflammation reduction trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors ... said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 ... drop zones. Editors can select from a variety of flip book animations. In Addition, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Bioelectronic ... Plus for consumers and healthcare professionals to manage chronic and acute pain. ... treatment modalities available in a single device. The announcement is part of ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “The Road ... is an everyday trial, not a one hour a week showing of hands. “The ... businessman. , Tom begins, “Perhaps you are familiar with the brass ring that you ...
(Date:12/7/2016)... ... ... With God: Inspirational Lessons from My Life's Journey”: a sometimes serious, sometimes humorous ... in their lives. “Walking With God: Inspirational Lessons from My Life's Journey” is the ... , Sanford says, “I enjoy sharing the true stories in my book as examples ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... for individuals impacted by cerebral cavernous angiomas, was awarded a grant from the ... patient engagement program. New Mexico has more people with cavernous angioma than anywhere ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... The pen needles market is projected to ... billion in 2016, growing at a CAGR of 11.2% ... Over the years, the pen needles market has witnessed ... growing demand for safety injections in the healthcare industry. ... pen needles with an aim to reduce pain, increase ...
(Date:12/6/2016)... -- Nearly 30 million people in the United ... 1 However, nearly 40% of diabetes patients in ... significant glucose variability. 2 These patients are at high ... left untreated, hyperglycemia can lead to cardiovascular disease, nerve ... As part of Diabetes Awareness Month, ...
(Date:12/6/2016)... opioids commonly used for pain management for workplace injuries, employers now ... to nationwide fatalities. The synthetic opioid called U-47700, or ... morphine, resulting in likelihood of addiction, abuse or death. ... , , ... for HMC HealthWorks, explained the opioid drug is less expensive yet ...
Breaking Medicine Technology: